Review





Similar Products

cd31 microbeads  (Miltenyi Biotec)
96
Miltenyi Biotec cd31 microbeads
Glioma‐intrinsic HEXB promoted Endo‐MT changes of ECs. (A) Survival of GBM patients received bevacizumab treatment with different HEXB expression in GSE79671 (log‐rank test). (B) Survival of GBM patients received bevacizumab treatment with different HEXB expression in GSE72951 (log‐rank test). (C) The rate of response patients was lower in GBM patients with high HEXB expression in GSE72951 (Patients with a survival time superior to the median survival of the standard treatment were defined as the responder group, whereas those with a shorter survival time were defined as the non‐responder group). (D) The analysis of migration ability of HBMECs treated with different CM (sh#1: shHEXB#1; sh#2: shHEXB#2). (E) Permeability changes of HBMECs treated with different CM (sh#1: shHEXB#1; sh#2: shHEXB#2). (F) Immunofluorescence staining image of HBMECs treated with different CM (sh#1: shHEXB#1; sh#2: shHEXB#2). (G) Western blot results of HBMECs treated with different CM (sh#1: shHEXB#1; sh#2: shHEXB#2). (H) PCR results of HBMECs treated with different CM (sh#1: shHEXB#1; sh#2: shHEXB#2). (I) Flow cytometry of <t>CD31</t> + cells in tumors from GSC1‐bearing mice. (J) Flow cytometry of CD31 + cells in tumors from GSC21‐bearing mice. (Date were presented as means ± standard deviations, * indicates p ≤ 0.05, ** indicates p < 0.01, **** indicates p < 0.0001.).
Cd31 Microbeads, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd31/CD31+MicroBeads%2C+mouse/pmc13650030-88-1-4
Average 96 stars, based on 1 article reviews
cd31 microbeads - by Bioz Stars, 2026-10
96/100 stars
  Buy from Supplier
cd31 antibody / pecam-1  (NSJ Bioreagents)
99
NSJ Bioreagents cd31 antibody / pecam-1
Glioma‐intrinsic HEXB promoted Endo‐MT changes of ECs. (A) Survival of GBM patients received bevacizumab treatment with different HEXB expression in GSE79671 (log‐rank test). (B) Survival of GBM patients received bevacizumab treatment with different HEXB expression in GSE72951 (log‐rank test). (C) The rate of response patients was lower in GBM patients with high HEXB expression in GSE72951 (Patients with a survival time superior to the median survival of the standard treatment were defined as the responder group, whereas those with a shorter survival time were defined as the non‐responder group). (D) The analysis of migration ability of HBMECs treated with different CM (sh#1: shHEXB#1; sh#2: shHEXB#2). (E) Permeability changes of HBMECs treated with different CM (sh#1: shHEXB#1; sh#2: shHEXB#2). (F) Immunofluorescence staining image of HBMECs treated with different CM (sh#1: shHEXB#1; sh#2: shHEXB#2). (G) Western blot results of HBMECs treated with different CM (sh#1: shHEXB#1; sh#2: shHEXB#2). (H) PCR results of HBMECs treated with different CM (sh#1: shHEXB#1; sh#2: shHEXB#2). (I) Flow cytometry of <t>CD31</t> + cells in tumors from GSC1‐bearing mice. (J) Flow cytometry of CD31 + cells in tumors from GSC21‐bearing mice. (Date were presented as means ± standard deviations, * indicates p ≤ 0.05, ** indicates p < 0.01, **** indicates p < 0.0001.).
Cd31 Antibody / Pecam 1, supplied by NSJ Bioreagents, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd31/CD31+Antibody+%2F+PECAM-1/custom%40v3143cf488%4042826194
Average 99 stars, based on 1 article reviews
cd31 antibody / pecam-1 - by Bioz Stars, 2026-10
99/100 stars
  Buy from Supplier
rabbit anticd31  (Cell Signaling Technology Inc)
97
Cell Signaling Technology Inc rabbit anticd31
Glioma‐intrinsic HEXB promoted Endo‐MT changes of ECs. (A) Survival of GBM patients received bevacizumab treatment with different HEXB expression in GSE79671 (log‐rank test). (B) Survival of GBM patients received bevacizumab treatment with different HEXB expression in GSE72951 (log‐rank test). (C) The rate of response patients was lower in GBM patients with high HEXB expression in GSE72951 (Patients with a survival time superior to the median survival of the standard treatment were defined as the responder group, whereas those with a shorter survival time were defined as the non‐responder group). (D) The analysis of migration ability of HBMECs treated with different CM (sh#1: shHEXB#1; sh#2: shHEXB#2). (E) Permeability changes of HBMECs treated with different CM (sh#1: shHEXB#1; sh#2: shHEXB#2). (F) Immunofluorescence staining image of HBMECs treated with different CM (sh#1: shHEXB#1; sh#2: shHEXB#2). (G) Western blot results of HBMECs treated with different CM (sh#1: shHEXB#1; sh#2: shHEXB#2). (H) PCR results of HBMECs treated with different CM (sh#1: shHEXB#1; sh#2: shHEXB#2). (I) Flow cytometry of <t>CD31</t> + cells in tumors from GSC1‐bearing mice. (J) Flow cytometry of CD31 + cells in tumors from GSC21‐bearing mice. (Date were presented as means ± standard deviations, * indicates p ≤ 0.05, ** indicates p < 0.01, **** indicates p < 0.0001.).
Rabbit Anticd31, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd31/CD31+(PECAM-1)+XP+Rabbit+mAb/pm42853343-153-6-8
Average 97 stars, based on 1 article reviews
rabbit anticd31 - by Bioz Stars, 2026-10
97/100 stars
  Buy from Supplier
antihuman cd31 pecam 1 dylight 550  (Novus Biologicals)
94
Novus Biologicals antihuman cd31 pecam 1 dylight 550
Glioma‐intrinsic HEXB promoted Endo‐MT changes of ECs. (A) Survival of GBM patients received bevacizumab treatment with different HEXB expression in GSE79671 (log‐rank test). (B) Survival of GBM patients received bevacizumab treatment with different HEXB expression in GSE72951 (log‐rank test). (C) The rate of response patients was lower in GBM patients with high HEXB expression in GSE72951 (Patients with a survival time superior to the median survival of the standard treatment were defined as the responder group, whereas those with a shorter survival time were defined as the non‐responder group). (D) The analysis of migration ability of HBMECs treated with different CM (sh#1: shHEXB#1; sh#2: shHEXB#2). (E) Permeability changes of HBMECs treated with different CM (sh#1: shHEXB#1; sh#2: shHEXB#2). (F) Immunofluorescence staining image of HBMECs treated with different CM (sh#1: shHEXB#1; sh#2: shHEXB#2). (G) Western blot results of HBMECs treated with different CM (sh#1: shHEXB#1; sh#2: shHEXB#2). (H) PCR results of HBMECs treated with different CM (sh#1: shHEXB#1; sh#2: shHEXB#2). (I) Flow cytometry of <t>CD31</t> + cells in tumors from GSC1‐bearing mice. (J) Flow cytometry of CD31 + cells in tumors from GSC21‐bearing mice. (Date were presented as means ± standard deviations, * indicates p ≤ 0.05, ** indicates p < 0.01, **** indicates p < 0.0001.).
Antihuman Cd31 Pecam 1 Dylight 550, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd31/CD31%2FPECAM-1+Antibody+(C31%2E3+%2B+JC%2F70A)+%5BDyLight+550%5D/pm42826194-367-36-43
Average 94 stars, based on 1 article reviews
antihuman cd31 pecam 1 dylight 550 - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier
cd31 antibody / pecam1  (NSJ Bioreagents)
91
NSJ Bioreagents cd31 antibody / pecam1
Glioma‐intrinsic HEXB promoted Endo‐MT changes of ECs. (A) Survival of GBM patients received bevacizumab treatment with different HEXB expression in GSE79671 (log‐rank test). (B) Survival of GBM patients received bevacizumab treatment with different HEXB expression in GSE72951 (log‐rank test). (C) The rate of response patients was lower in GBM patients with high HEXB expression in GSE72951 (Patients with a survival time superior to the median survival of the standard treatment were defined as the responder group, whereas those with a shorter survival time were defined as the non‐responder group). (D) The analysis of migration ability of HBMECs treated with different CM (sh#1: shHEXB#1; sh#2: shHEXB#2). (E) Permeability changes of HBMECs treated with different CM (sh#1: shHEXB#1; sh#2: shHEXB#2). (F) Immunofluorescence staining image of HBMECs treated with different CM (sh#1: shHEXB#1; sh#2: shHEXB#2). (G) Western blot results of HBMECs treated with different CM (sh#1: shHEXB#1; sh#2: shHEXB#2). (H) PCR results of HBMECs treated with different CM (sh#1: shHEXB#1; sh#2: shHEXB#2). (I) Flow cytometry of <t>CD31</t> + cells in tumors from GSC1‐bearing mice. (J) Flow cytometry of CD31 + cells in tumors from GSC21‐bearing mice. (Date were presented as means ± standard deviations, * indicates p ≤ 0.05, ** indicates p < 0.01, **** indicates p < 0.0001.).
Cd31 Antibody / Pecam1, supplied by NSJ Bioreagents, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd31/CD31+Antibody+%2F+PECAM1/custom%40v3143%4042826194
Average 91 stars, based on 1 article reviews
cd31 antibody / pecam1 - by Bioz Stars, 2026-10
91/100 stars
  Buy from Supplier
cd31  (Proteintech)
94
Proteintech cd31
Glioma‐intrinsic HEXB promoted Endo‐MT changes of ECs. (A) Survival of GBM patients received bevacizumab treatment with different HEXB expression in GSE79671 (log‐rank test). (B) Survival of GBM patients received bevacizumab treatment with different HEXB expression in GSE72951 (log‐rank test). (C) The rate of response patients was lower in GBM patients with high HEXB expression in GSE72951 (Patients with a survival time superior to the median survival of the standard treatment were defined as the responder group, whereas those with a shorter survival time were defined as the non‐responder group). (D) The analysis of migration ability of HBMECs treated with different CM (sh#1: shHEXB#1; sh#2: shHEXB#2). (E) Permeability changes of HBMECs treated with different CM (sh#1: shHEXB#1; sh#2: shHEXB#2). (F) Immunofluorescence staining image of HBMECs treated with different CM (sh#1: shHEXB#1; sh#2: shHEXB#2). (G) Western blot results of HBMECs treated with different CM (sh#1: shHEXB#1; sh#2: shHEXB#2). (H) PCR results of HBMECs treated with different CM (sh#1: shHEXB#1; sh#2: shHEXB#2). (I) Flow cytometry of <t>CD31</t> + cells in tumors from GSC1‐bearing mice. (J) Flow cytometry of CD31 + cells in tumors from GSC21‐bearing mice. (Date were presented as means ± standard deviations, * indicates p ≤ 0.05, ** indicates p < 0.01, **** indicates p < 0.0001.).
Cd31, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd31/CD31+Fusion+Protein/10__1093_slash_rb_slash_rbag218-138-6-9
Average 94 stars, based on 1 article reviews
cd31 - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier
anti cd31 antibody  (R&D Systems)
98
R&D Systems anti cd31 antibody
Glioma‐intrinsic HEXB promoted Endo‐MT changes of ECs. (A) Survival of GBM patients received bevacizumab treatment with different HEXB expression in GSE79671 (log‐rank test). (B) Survival of GBM patients received bevacizumab treatment with different HEXB expression in GSE72951 (log‐rank test). (C) The rate of response patients was lower in GBM patients with high HEXB expression in GSE72951 (Patients with a survival time superior to the median survival of the standard treatment were defined as the responder group, whereas those with a shorter survival time were defined as the non‐responder group). (D) The analysis of migration ability of HBMECs treated with different CM (sh#1: shHEXB#1; sh#2: shHEXB#2). (E) Permeability changes of HBMECs treated with different CM (sh#1: shHEXB#1; sh#2: shHEXB#2). (F) Immunofluorescence staining image of HBMECs treated with different CM (sh#1: shHEXB#1; sh#2: shHEXB#2). (G) Western blot results of HBMECs treated with different CM (sh#1: shHEXB#1; sh#2: shHEXB#2). (H) PCR results of HBMECs treated with different CM (sh#1: shHEXB#1; sh#2: shHEXB#2). (I) Flow cytometry of <t>CD31</t> + cells in tumors from GSC1‐bearing mice. (J) Flow cytometry of CD31 + cells in tumors from GSC21‐bearing mice. (Date were presented as means ± standard deviations, * indicates p ≤ 0.05, ** indicates p < 0.01, **** indicates p < 0.0001.).
Anti Cd31 Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd31/Human%2FMouse%2FRat+CD31%2FPECAM-1+Antibody/pmc13621939-56-29-31
Average 98 stars, based on 1 article reviews
anti cd31 antibody - by Bioz Stars, 2026-10
98/100 stars
  Buy from Supplier
updated february 2025 goat anti cd31  (R&D Systems)
98
R&D Systems updated february 2025 goat anti cd31
Glioma‐intrinsic HEXB promoted Endo‐MT changes of ECs. (A) Survival of GBM patients received bevacizumab treatment with different HEXB expression in GSE79671 (log‐rank test). (B) Survival of GBM patients received bevacizumab treatment with different HEXB expression in GSE72951 (log‐rank test). (C) The rate of response patients was lower in GBM patients with high HEXB expression in GSE72951 (Patients with a survival time superior to the median survival of the standard treatment were defined as the responder group, whereas those with a shorter survival time were defined as the non‐responder group). (D) The analysis of migration ability of HBMECs treated with different CM (sh#1: shHEXB#1; sh#2: shHEXB#2). (E) Permeability changes of HBMECs treated with different CM (sh#1: shHEXB#1; sh#2: shHEXB#2). (F) Immunofluorescence staining image of HBMECs treated with different CM (sh#1: shHEXB#1; sh#2: shHEXB#2). (G) Western blot results of HBMECs treated with different CM (sh#1: shHEXB#1; sh#2: shHEXB#2). (H) PCR results of HBMECs treated with different CM (sh#1: shHEXB#1; sh#2: shHEXB#2). (I) Flow cytometry of <t>CD31</t> + cells in tumors from GSC1‐bearing mice. (J) Flow cytometry of CD31 + cells in tumors from GSC21‐bearing mice. (Date were presented as means ± standard deviations, * indicates p ≤ 0.05, ** indicates p < 0.01, **** indicates p < 0.0001.).
Updated February 2025 Goat Anti Cd31, supplied by R&D Systems, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd31/Human%2FMouse%2FRat+CD31%2FPECAM-1+Antibody/pm42809441-78-0-6
Average 98 stars, based on 1 article reviews
updated february 2025 goat anti cd31 - by Bioz Stars, 2026-10
98/100 stars
  Buy from Supplier
cd31 pecam 1  (R&D Systems)
98
R&D Systems cd31 pecam 1
Glioma‐intrinsic HEXB promoted Endo‐MT changes of ECs. (A) Survival of GBM patients received bevacizumab treatment with different HEXB expression in GSE79671 (log‐rank test). (B) Survival of GBM patients received bevacizumab treatment with different HEXB expression in GSE72951 (log‐rank test). (C) The rate of response patients was lower in GBM patients with high HEXB expression in GSE72951 (Patients with a survival time superior to the median survival of the standard treatment were defined as the responder group, whereas those with a shorter survival time were defined as the non‐responder group). (D) The analysis of migration ability of HBMECs treated with different CM (sh#1: shHEXB#1; sh#2: shHEXB#2). (E) Permeability changes of HBMECs treated with different CM (sh#1: shHEXB#1; sh#2: shHEXB#2). (F) Immunofluorescence staining image of HBMECs treated with different CM (sh#1: shHEXB#1; sh#2: shHEXB#2). (G) Western blot results of HBMECs treated with different CM (sh#1: shHEXB#1; sh#2: shHEXB#2). (H) PCR results of HBMECs treated with different CM (sh#1: shHEXB#1; sh#2: shHEXB#2). (I) Flow cytometry of <t>CD31</t> + cells in tumors from GSC1‐bearing mice. (J) Flow cytometry of CD31 + cells in tumors from GSC21‐bearing mice. (Date were presented as means ± standard deviations, * indicates p ≤ 0.05, ** indicates p < 0.01, **** indicates p < 0.0001.).
Cd31 Pecam 1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd31/Human%2FMouse%2FRat+CD31%2FPECAM-1+Antibody/pm42788754-43-30-32
Average 98 stars, based on 1 article reviews
cd31 pecam 1 - by Bioz Stars, 2026-10
98/100 stars
  Buy from Supplier

Image Search Results


Glioma‐intrinsic HEXB promoted Endo‐MT changes of ECs. (A) Survival of GBM patients received bevacizumab treatment with different HEXB expression in GSE79671 (log‐rank test). (B) Survival of GBM patients received bevacizumab treatment with different HEXB expression in GSE72951 (log‐rank test). (C) The rate of response patients was lower in GBM patients with high HEXB expression in GSE72951 (Patients with a survival time superior to the median survival of the standard treatment were defined as the responder group, whereas those with a shorter survival time were defined as the non‐responder group). (D) The analysis of migration ability of HBMECs treated with different CM (sh#1: shHEXB#1; sh#2: shHEXB#2). (E) Permeability changes of HBMECs treated with different CM (sh#1: shHEXB#1; sh#2: shHEXB#2). (F) Immunofluorescence staining image of HBMECs treated with different CM (sh#1: shHEXB#1; sh#2: shHEXB#2). (G) Western blot results of HBMECs treated with different CM (sh#1: shHEXB#1; sh#2: shHEXB#2). (H) PCR results of HBMECs treated with different CM (sh#1: shHEXB#1; sh#2: shHEXB#2). (I) Flow cytometry of CD31 + cells in tumors from GSC1‐bearing mice. (J) Flow cytometry of CD31 + cells in tumors from GSC21‐bearing mice. (Date were presented as means ± standard deviations, * indicates p ≤ 0.05, ** indicates p < 0.01, **** indicates p < 0.0001.).

Journal: Advanced Science

Article Title: Tumor‐Intrinsic HEXB Drives Endothelial‐To‐Mesenchymal Transition and Confers Resistance to Anti‐Angiogenic Therapy in Glioblastoma

doi: 10.1002/advs.78208

Figure Lengend Snippet: Glioma‐intrinsic HEXB promoted Endo‐MT changes of ECs. (A) Survival of GBM patients received bevacizumab treatment with different HEXB expression in GSE79671 (log‐rank test). (B) Survival of GBM patients received bevacizumab treatment with different HEXB expression in GSE72951 (log‐rank test). (C) The rate of response patients was lower in GBM patients with high HEXB expression in GSE72951 (Patients with a survival time superior to the median survival of the standard treatment were defined as the responder group, whereas those with a shorter survival time were defined as the non‐responder group). (D) The analysis of migration ability of HBMECs treated with different CM (sh#1: shHEXB#1; sh#2: shHEXB#2). (E) Permeability changes of HBMECs treated with different CM (sh#1: shHEXB#1; sh#2: shHEXB#2). (F) Immunofluorescence staining image of HBMECs treated with different CM (sh#1: shHEXB#1; sh#2: shHEXB#2). (G) Western blot results of HBMECs treated with different CM (sh#1: shHEXB#1; sh#2: shHEXB#2). (H) PCR results of HBMECs treated with different CM (sh#1: shHEXB#1; sh#2: shHEXB#2). (I) Flow cytometry of CD31 + cells in tumors from GSC1‐bearing mice. (J) Flow cytometry of CD31 + cells in tumors from GSC21‐bearing mice. (Date were presented as means ± standard deviations, * indicates p ≤ 0.05, ** indicates p < 0.01, **** indicates p < 0.0001.).

Article Snippet: The CD31 Microbeads (130‐097‐418, Miltenyi) were used for positive selection CD31 + endothelial cells from single‐cell suspensions of mouse tissues.

Techniques: Expressing, Analysis, Migration, Permeability, Immunofluorescence, Staining, Western Blot, Flow Cytometry